# A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct07693777` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07693777](<https://clinicaltrials.gov/study/NCT07693777>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07693777

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 480 participants.

## Technical summary

Registry record NCT07693777. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-17 (anticipated); primary completion 2029-02-14 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 480 participants (planned count; ClinicalTrials.gov record NCT07693777, source copy `cardio:ctgov-nct07693777-2026-07-10`, retrieved 2026-10-31)
- Planned start: 2026-08-17 (anticipated) (ClinicalTrials.gov record NCT07693777, source copy `cardio:ctgov-nct07693777-2026-07-10`, retrieved 2026-10-31)
- Primary completion: 2029-02-14 (anticipated) (ClinicalTrials.gov record NCT07693777, source copy `cardio:ctgov-nct07693777-2026-07-10`, retrieved 2026-10-31)
- Completion: 2029-12-05 (anticipated) (ClinicalTrials.gov record NCT07693777, source copy `cardio:ctgov-nct07693777-2026-07-10`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07693777, source copy `cardio:ctgov-nct07693777-2026-07-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07693777-2026-07-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
- Condition: Severe Hypertriglyceridemia (sHTG)
- Condition: Hypertriglyceridemia
- Intervention (Biological): DR10624 Injection
- Intervention (Other): Matching Placebo for DR10624
- Lead sponsor: Zhejiang Doer Biologics Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Zhejiang Doer Biologics Co., Ltd. (`cardio:org-zhejiang-doer-biologics-co-ltd`)

## Provenance

Content hash: cb899d130b83131b4fb635a8e241661858d0c1c999179d05fc44084784c565df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
